In vitro cytotoxic activities of 2-alkyl-4,6-diheteroalkyl-1,3,5-triazines: New molecules in anticancer research

Journal of Medicinal Chemistry

Volumn 47, Issue 19, 2004, Pages 4649-4652

  Menicagli, Rita ^a   Samaritani, Simona ^a   Signore, Giovanni ^a   Vaglini, Francesca ^a   Dalla Via, Lisa ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 4,6 DIMETHOXY 1,3,5 TRIAZINE; 2,4 BIS(N HYDROXYMETHYL N METHYLAMINO) 6 N METHYLAMINO 1,3,5 TRIAZINE; ALTRETAMINE; ANTINEOPLASTIC AGENT; ORGANOTIN COMPOUND; PALLADIUM; TRIAZINE DERIVATIVE; TRIMELAMOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOTOXICITY; DRUG DNA INTERACTION; DRUG STRUCTURE; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; LEUKEMIA L 1210; STILLE REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CELL DEATH; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4444288821     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0495374     Document Type: Article

References (28)

1. Coley, H. M. N-(Hydroxymethyl)melamines. Gen. Pharmacol. 1997, 28, 177-182 and references therein.
2. Foster, B. J.; Harding, B. J.; Leyland-Jones, B.; Hoth, D. Hexamethylmelamine: critical review of an active drug. Cancer Treat. Rev. 1986, 38, 197-217.
3. Ames, M. M. Hexamethylmelamine: pharmacology and mechanism of action. Cancer Treat. Rev. 1991, 18, 3-14.
4. Judson, I. R.; Thornton, T. J.; Wilman, D. E. V.; Abel, G.; Rutty, C. J. Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl. J. Med. Chem. 1993, 36, 4195-4200.
5. Jarman, M.; Brooks, N.; Thornton, T. J.; Judson, I. R. Stable analogues of the antitumour agent trimelamol retain in vitro cytotoxicity in drug-sensitive and resistant rodent and human cell lines. Eur J. Cancer 1994, 30A, 1827-1836.
6. Labrid, C.; Régnier, G. L.; Laubie, M. Almitrine bismesylate: Pharmacological review and structure-activity relationships. Eur. J. Respir. Dis. 1983, 64 (Suppl. 126), 185-189.
7. D'Atri, G.; Gomarasca, P.; Resnati, G.; Tronconi, G.; Scolastico, C.; Sirtori, C. R. Novel pyrimidine and 1,3,5-triazine hypolipemic agents. J. Med. Chem. 1984, 27, 1621-1629.
8. Dhainaut, A.; Régnier, G.; Atassi, G.; Pierre, A.; Leonce, S.; Kraus-Berthier, L.; Prost, J. F. New triazine derivatives as potent modulators of multidrug resistance. J. Med. Chem. 1992, 35, 2481-2496.
9. Porter, J. R.; Archibald, S. C.; Brown, J. A.; Childs, K.; Critchley, D.; Head, J. C.; Hutchinson, B.; Parton, T. A. H.; Robinson, M. K.; Shock, A.; Warrellow, J.; Zomaya, A. Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists. Bioorg. Med. Chem. Lett. 2002,12,1591-1594.
10. Hajduk, P. J.; Dinges, J.; Schkeryantz, J. M.; Janowick, D.; Kaminski, M.; Tufano, M.; Augeri, D. J.; Petros, A.; Nienaber, V.; Zhong, P.; Hammond, R.; Coen, M.; Beutel, B.; Katz, L.; Fesik, S. W. Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis. J. Med. Chem. 1999, 42, 3852-3859.
11. Wang, Q.; Liu, G.; Shao, R.; Huang, R. Synthesis and antivirus activity of 1,3,5-triazine derivatives. Heteroat. Chem. 2003, 14, 542-545.
12. Klenke, B.; Stewart, M.; Barrett, M. P.; Brun, R.; Gilbert, I. H. Synthesis and Biological Evaluation of s-Triazine Substituted Polyamines as Potential New Anti-Trypanosomal Drugs. J. Med. Chem. 2001, 44, 3440-3452.
13. Henke, B. R.; Consler, T. G.; Go, N.; Hale, R. L.; Hohman, D. R.; Jones, S. A.; Lu, A. T.; Moore, L. B.; Moore, J. T.; Orband-Miller, L. A.; Robinett, R. G.; Shearin J.; Spearing, P. K.; Stewart, E. L.; Turnbull, P. S.; Weaver, S. L.; Williams, S. P.; Wisely, G. B.; Lambert M. H. A New Series of Estrogen Receptor Modulators That Display Selectivity for Estrogen Receptor. J. Med. Chem. 2002, 45, 5492-5505.
14. Mylari, B. L.; Withbroe, G. J.; Beebe, D. A.; Brackett, N. S.; Conn, E. L.; Coutcher, J. B.; Gates, P. J.; Zembrowski, W. J. Design and Synthesis of a Novel Family of Triazine-Based Inhibitors of Sorbitol Dehydrogenase with Oral Activity: 1-{4-[3R,5S-Dimethyl-4-(4-methyl-1,3,5]triazin-2-yl)-piperazin-1-yl]- [1,3,5]-triazin-2-yl}-(R) Ethanol. Bioorg. Med. Chem. 2003, 11, 4179-4188.
15. Kukla, M. J.; Ludovici, D. W.; Janssen, P. A. J.; Heeres, J.; Moereels, H. E. L. Substituted diamino-1,3,5-triazine derivatives. European Patent Application EP 0 834 507 A1, 1998.
16. Menicagli, R.; Samaritani, S.; Zucchelli, V. 2-Alkyl-4,6-dialkyl-amino-1, 3,5-triazines via Grignard alkylation of cyanuric chloride: an aged reaction revisited. Tetrahedron 2000, 56, 9705-9711.
17. Menicagli, R.; Samaritani, S.; Gori, S. 2-(Alk-1′-ynyl)-4,6- dimethoxy-1,3,5-triazines via Pd-mediated alkynylation of 2-chloro-4,6- dimethoxy-1,3,5-triazine. Tetrahedron Lett. 1999, 40, 8419-8422.
18. Samaritani, S.; Menicagli, R. Palladium on Carbon Catalyzed Cross-Coupling between Alk-1-ynes and 2-Chloro-4,6-dialkoxy-1,3,5-triazines. Tetrahedron 2002, 58, 1381-1386.
19. Menicagli, R.; Malanga, C.; Peluso, P. Selective mono- or dialkoxylation of 2,4,6-trichloro-1,3,5-triazine in solid-liquid phase transfer conditions. Synth. Commun. 1994,24, 2153-2158 and references therein.
20. Samaritani, S.; Peluso, P.; Malanga, C.; Menicagli, R. Selective Amination of Cyanuric Chloride in the Presence of 18-Crown-6. Eur. J. Org. Chem. 2002, 1551-1555.
21. Signore, G.; Samaritani, S.; Menicagli, R. Palladium and Nickel-Catalyzed Cross-Coupling Reactions: A Useful Approach to 2-Alkyl-4,6-dialkoxy-1,3,5- triazines. Presented at the 4th Franco-Italian Meeting on Organic Chemistry. Organic Chemistry: New Frontiers and Challenging applications, Annecy, France, May 5-8, 2004; Abstract P25.
22. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
23. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the National-Cancer-Institute in-vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 34, 91-109.
24. Monks, A.; Scudiero, D. A.; Johnson, G. S.; Paull, K. D.; Sausville, E. A. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anti-Cancer Drug Des. 1997, 12, 533-541.
25. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 87, 1088-1092.
26. Riou, J. F.; Guittat, L.; Mailliet, P.; Laoui, A.; Renou, E.; Petitgenet, O.; Megnin-Chanet, F.; Helene, C.; Mergny, J. L. Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 2672-2677.
27. Gomez, D.; Lemarteleur, T.; Lacroix, L.; Mailliet, P.; Mergny, J. L.; Riou, J. F. Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing. Nucleic Acids Res. 2004, 32, 371-379.
28. Jarman, M.; Coley, H. M. Melamine derivatives for use in the treatment of cancer. U.S. Patent 5, 854, 244, 1998.